SK pharmteco

SK pharmteco describes itself as a leading global contract development and manufacturing organization (CDMO) with a network of CGMP facilities in key markets. As a subsidiary of SK Inc., it states it is backed by the strength and stability of one of South Korea's largest business networks. Its integrated service offerings cover process and analytical method development, optimization, validation, analytical testing, and commercial production, spanning small molecules, peptides, viral vectors, and cell and gene therapies.

SK pharmteco states that, as a subsidiary of SK Inc., it is backed by the strength and stability of one of South Korea's largest business networks, and that it draws from a long-standing industry presence, leveraging expertise, technology, and a legacy of innovation to navigate the complexities of advancing small molecule and cell and gene therapies.

A leading global CDMO with a network of CGMP facilities in key markets, operating as 'One Team' with customers.

• 2021-03-31

  SK completes acquisition of Yposkesi[5]SK完成对Yposkesi的收购econotimes.com

  Reported: 2021-04-01

  SK completed its acquisition of French drug manufacturer Yposkesi, acquiring a 70% stake including management rights. Yposkesi will be operated by SK Pharmteco, an SK Inc. subsidiary.

1. 1SK pharmteco | Leading CDMO Services - Empower Your Pathskpharmteco.com
2. 2Compliance, Ethics & Transparency | SK pharmtecoskpharmteco.com
3. 3About Us | SK pharmtecoskpharmteco.com
4. 4Careers | SK pharmtecoskpharmteco.com
5. 5SK完成对Yposkesi的收购econotimes.com